摘要
目的观察喘可治注射液辅助治疗慢性阻塞性肺疾病(COPD)患者免疫功能的改善情况。方法共选40例COPD患者,随机分为治疗组和对照组各20例。2组均给予抗炎解痉止咳等治疗,治疗组加用喘可治注射液肌肉注射,喘可治4ml,qd,疗程14d,对照组只予上述常规治疗14d。观察治疗前后患者临床症状的改善情况,淋巴细胞亚群测定(CD3、CD4、CD8、CD19)情况。结果所有患者治疗前CD3和CD4淋巴细胞亚群水平均偏低,说明其细胞免疫功能异常,治疗后治疗组患者CD3和CD4淋巴细胞亚群水平较对照组明显(P<0.01),以CD19为标志的体液免疫指标也明显改善(P<0.01),两组治疗前后相比有显著差异(P<0.01)。结论喘可治注射液辅助治疗COPD患者可以改善患者免疫功能,且无不良反应,值得推广应用。
Objective To observe the influences of huankezhi injection on immune functions in chronic obstructive pulmonary disease patients. Methods 40 cases were randomly divided into treated group （n =20） and control group （n =20）. Based on conventional therapy for the two groups, the chuankezhi injection（4ml, qd）were used intravenously once a day was added in the treated group. The therapeutic course was 14 days for two groups. Before and after therapy, the T cell subgroup of peripheral blood （CD3 , CD4 , CDs , CDI9 ） were detected separately in the two groups. Results After therapy in the treated group CD3 , CD4 and CD19 were significantly increased （ P 〈 0. 01 ）. The differences between two groups were significant （ P 〈 0. 01 ）. Conclusion Chuankezhi injection is able to elevate the immune functions in chronic obstructive pulmonary disease patients. It is safe and effective method in treating COPD.
出处
《临床肺科杂志》
2007年第11期1162-1163,共2页
Journal of Clinical Pulmonary Medicine
关键词
喘可治注射液
慢性阻塞性肺疾病
免疫
淋巴细胞亚群
chuankezhi injection
chronic obstructive pulmonary disease
immune
lymphocyte subgroup
